Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Cited In for PubMed (Select 18268197)

1.

Circulating biomarkers that predict incident dementia.

Weinstein G, Seshadri S.

Alzheimers Res Ther. 2014 Jan 21;6(1):6. doi: 10.1186/alzrt235. eCollection 2014. Review.

2.

Cerebrospinal fluid and blood biomarkers in Alzheimer's disease.

Humpel C, Hochstrasser T.

World J Psychiatry. 2011 Dec 31;1(1):8-18. doi: 10.5498/wjp.v1.i1.8. Review.

3.

Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.

Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa IT, Przybylski M, Manea M, von Arnim CA.

PLoS One. 2013 Jul 18;8(7):e68996. doi: 10.1371/journal.pone.0068996. Print 2013.

4.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

5.

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker.

Toledo JB, Shaw LM, Trojanowski JQ.

Alzheimers Res Ther. 2013 Mar 8;5(2):8. doi: 10.1186/alzrt162. eCollection 2013. Review.

6.

Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD.

Pesini P, Pérez-Grijalba V, Monleón I, Boada M, Tárraga L, Martínez-Lage P, San-José I, Sarasa M.

Int J Alzheimers Dis. 2012;2012:604141. doi: 10.1155/2012/604141. Epub 2012 Aug 16.

7.

The demographic and medical correlates of plasma aβ40 and aβ42.

Metti AL, Cauley JA, Ayonayon HN, Harris TB, Rosano C, Williamson JD, Yaffe K; Health, Aging and Body Composition Study.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):244-9. doi: 10.1097/WAD.0b013e318260a8cb.

8.

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F.

Arch Neurol. 2012 Jul;69(7):824-31. Review.

9.

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease.

Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS.

J Neural Transm. 2012 Jul;119(7):843-50. doi: 10.1007/s00702-012-0772-4. Epub 2012 Feb 22. Review.

10.

Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Mayeux R, Schupf N.

Neurobiol Aging. 2011 Dec;32 Suppl 1:S10-9. doi: 10.1016/j.neurobiolaging.2011.09.004. Review.

11.

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.

Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 Oct;122(4):401-13. doi: 10.1007/s00401-011-0861-8. Epub 2011 Jul 30.

12.

Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.

Devanand DP, Schupf N, Stern Y, Parsey R, Pelton GH, Mehta P, Mayeux R.

Neurology. 2011 Jul 12;77(2):125-31. doi: 10.1212/WNL.0b013e318224afb7. Epub 2011 Jun 29.

13.

Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W.

Neurology. 2010 Nov 2;75(18):1639-44. doi: 10.1212/WNL.0b013e3181fb448b.

14.

Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain.

Ariga T, Yanagisawa M, Wakade C, Ando S, Buccafusco JJ, McDonald MP, Yu RK.

ASN Neuro. 2010 Oct 4;2(4):e00044. doi: 10.1042/AN20100021.

15.

Plasma ß-amyloid and cognitive decline.

Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, Schupf N, Mayeux RP.

Arch Neurol. 2010 Dec;67(12):1485-90. doi: 10.1001/archneurol.2010.189. Epub 2010 Aug 9.

16.

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.

Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1123-7. doi: 10.1136/jnnp.2010.205757. Epub 2010 May 16.

17.

Blood-based biomarkers of Alzheimer's disease: challenging but feasible.

Thambisetty M, Lovestone S.

Biomark Med. 2010 Feb;4(1):65-79. Review.

18.

Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.

Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG.

Biomarkers. 2009 Nov;14(7):493-501. doi: 10.3109/13547500903108423.

19.

Ten-year change in plasma amyloid beta levels and late-life cognitive decline.

Okereke OI, Xia W, Selkoe DJ, Grodstein F.

Arch Neurol. 2009 Oct;66(10):1247-53. doi: 10.1001/archneurol.2009.207.

20.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K.

Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk